MDR-TB

Lilly: Announcing the 2015 REACH Lilly MDR TB Partnership Media Award Winners

Blog

Today’s guest blog comes from Sunita Prasad, senior manager for Lilly’s MDR-TB Partnership in India.

Tuberculosis (TB) continues to pose a monumental global health challenge. The disease affected nine million people in 2013, and claimed 1.5 million lives. In India, 1,000 people die of TB daily, though the disease is fully curable.

Lilly: Forging Alliances is Crucial to Fighting Tuberculosis

Blog

Today’s guest Blogger is Dr. Lasha Goguadze, Senior Health Officer, Global Tuberculosis Programme, International Federation of the Red Cross and Red Crescent Societies. He is based in Geneva.

Lilly: Drug-Resistant TB Demands More R&D

Blog

Today's guest blog comes from Lilly's vice president of Global Health Programs, Evan Lee, M.D. 

A new article published by a team from the World Health Organization in the European Respiratory Journal shows that while we’re seeing gradual expansion in care for multidrug-resistant TB (MDR-TB), there continues to be an urgent need to accelerate the scale up of diagnosis and treatment efforts in heavily affected countries. 

Lilly: Taking the Fight to MDR-TB

Blog

Today's guest blog comes from Lilly's vice president of Global Health Programs, Evan Lee, M.D.

“Americans can no longer afford to be indifferent to the rise of drug-resistant tuberculosis.”

Lilly: Renewed Awakening to the Global TB Crisis

Blog

Today's guest blog comes from Lilly's vice president of Global Health Programs, Evan Lee, M.D.

Having recently returned from the annual Union World Conference on Lung Health, I am struck by the signs of increased solidarity and urgency in the fight against tuberculosis (TB). As a physician, I can’t help but see parallels between the disease we are fighting and the promise of increased momentum in national and international efforts.

Lilly: Chinese and Russian Experts Exchange MDR-TB Best Practices

Blog
 
Today’s guest blog comes from Mikhail Volik and Zhi Jun He, Lilly MDR-TB program officers in Russia and China, respectively.
 

Lilly: A Good Start to Ending TB in China

Blog
 
Today’s guest blog comes from He Zhijun, Lilly’s CSR Manager and Program Officer for the Lilly MDR-TB Partnership in China.
 
In late June, I organized our first media visit to the Heilongjiang Provincial Infectious Disease Hospital located in Harbin, the provincial capital of China’s Heilongjiang province. The hospital is one of six pilot centers from the Lilly-China Medical Association TB Society collaboration focused on enhancing clinical skills of tuberculosis (TB) physicians.
 

High Hopes in Russia with New Global TB Strategy

Blog

In mid-May, historic medical news spread around the world: the World Health Assembly passed a resolution approving the new post-2015 Global Strategy for TB Prevention, Care and Control with ambitious targets and a vision of ending the TB epidemic by 2035. This strategic plan contains unprecedented goals such as decreasing TB mortality by 95 percent from current levels. If the goals are achieved, it would truly be a major breakthrough – something that was unimaginable just 20 years ago, when we thought curing multidrug-resistant TB (MDR-TB) wasn’t possible.

Lilly: Political Commitment to End TB

By David Marbaugh
Blog

Today's guest blog comes from Lilly's Vice President of Global Health Programs and Access, Dr. Evan Lee.

In an encouraging move, the World Health Assembly has passed a formal, long-term resolution to stop TB. This means that all countries that participate in the World Health Organization have agreed to a concrete strategy – with clear targets – that could potentially rid the world of this dreadful disease.

Lilly Celebrates Nurses As Change Agents

By David Marbaugh
Blog

Today’s guest blog comes from Gini Williams, director for TB projects with the International Council of Nurses. Lilly partners with ICN through the Lilly MDR-TB Partnership.

Pages

Subscribe to MDR-TB